NewsBite

Street Talk

Biotech Kazia taps Bells for entitlement offer

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Sydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund its participation in an international bran cancer study.

Brain cancer drug developer Kazia Therapeutics launched a capital raising on Wednesday.  

Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Anthony Macdonald is a Chanticleer columnist. He is a former Street Talk co-editor and has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies. Connect with Anthony on Twitter. Email Anthony at a.macdonald@afr.com
Tim Boyd is a journalist, based in Sydney, who writes for the Street Talk column. Connect with Tim on Twitter. Email Tim at tim.boyd@afr.com

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Original URL: https://www.afr.com/street-talk/biotech-kazia-therapeutics-taps-bell-potter-for-entitlement-offer-20200930-p560kf